AnaptysBio Statistics
Total Valuation
AnaptysBio has a market cap or net worth of $618.01 million. The enterprise value is $554.95 million.
Important Dates
The last earnings date was Tuesday, November 5, 2024, after market close.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AnaptysBio has 30.43 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 30.43M |
| Shares Outstanding | 30.43M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +5.62% |
| Owned by Insiders (%) | 1.78% |
| Owned by Institutions (%) | 78.06% |
| Float | 19.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.74 |
| Forward PS | 24.16 |
| PB Ratio | 7.33 |
| P/TBV Ratio | 7.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.23, with a Debt / Equity ratio of 4.35.
| Current Ratio | 10.23 |
| Quick Ratio | 10.08 |
| Debt / Equity | 4.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.72 |
Financial Efficiency
Return on equity (ROE) is -161.81% and return on invested capital (ROIC) is -19.43%.
| Return on Equity (ROE) | -161.81% |
| Return on Assets (ROA) | -17.85% |
| Return on Capital (ROIC) | -19.43% |
| Revenue Per Employee | $488,650 |
| Profits Per Employee | -$1.42M |
| Employee Count | 117 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AnaptysBio has paid $5,000 in taxes.
| Income Tax | 5,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.31% in the last 52 weeks. The beta is -0.24, so AnaptysBio's price volatility has been lower than the market average.
| Beta (5Y) | -0.24 |
| 52-Week Price Change | +36.31% |
| 50-Day Moving Average | 30.12 |
| 200-Day Moving Average | 27.78 |
| Relative Strength Index (RSI) | 33.24 |
| Average Volume (20 Days) | 659,352 |
Short Selling Information
The latest short interest is 6.18 million, so 20.29% of the outstanding shares have been sold short.
| Short Interest | 6.18M |
| Short Previous Month | 5.98M |
| Short % of Shares Out | 20.29% |
| Short % of Float | 31.06% |
| Short Ratio (days to cover) | 13.41 |
Income Statement
In the last 12 months, AnaptysBio had revenue of $57.17 million and -$165.66 million in losses. Loss per share was -$6.04.
| Revenue | 57.17M |
| Gross Profit | -97.60M |
| Operating Income | -140.08M |
| Pretax Income | -170.11M |
| Net Income | -165.66M |
| EBITDA | -139.45M |
| EBIT | -140.08M |
| Loss Per Share | -$6.04 |
Full Income StatementBalance Sheet
The company has $430.12 million in cash and $367.06 million in debt, giving a net cash position of $63.06 million or $2.07 per share.
| Cash & Cash Equivalents | 430.12M |
| Total Debt | 367.06M |
| Net Cash | 63.06M |
| Net Cash Per Share | $2.07 |
| Equity (Book Value) | 84.37M |
| Book Value Per Share | 2.77 |
| Working Capital | 404.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$103.01 million and capital expenditures -$375,000, giving a free cash flow of -$103.39 million.
| Operating Cash Flow | -103.01M |
| Capital Expenditures | -375,000 |
| Free Cash Flow | -103.39M |
| FCF Per Share | -$3.40 |
Full Cash Flow StatementMargins
Gross margin is -170.72%, with operating and profit margins of -245.01% and -289.75%.
| Gross Margin | -170.72% |
| Operating Margin | -245.01% |
| Pretax Margin | -289.74% |
| Profit Margin | -289.75% |
| EBITDA Margin | -243.91% |
| EBIT Margin | -245.01% |
| FCF Margin | -426.28% |
Dividends & Yields
AnaptysBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.08% |
| Shareholder Yield | -0.08% |
| Earnings Yield | -26.81% |
| FCF Yield | -16.73% |
Analyst Forecast
The average price target for AnaptysBio is $54.64, which is 169.03% higher than the current price. The consensus rating is "Buy".
| Price Target | $54.64 |
| Price Target Difference | 169.03% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 39.61% |
| EPS Growth Forecast (5Y) | 1.60% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AnaptysBio has an Altman Z-Score of -0.93 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.93 |
| Piotroski F-Score | 3 |